Description

IL-4 is a pivotal cytokine in type 2 immune responses, influencing T cell differentiation, antibody class switching, and macrophage activation. Traditional recombinant engineering limits precise tailoring of IL-4. Cytokines need better pharmacology and new-to-nature features!

Highlight: ncAAs introduce groups conferring novel capabilities like receptor selectivity, conditional activation, and enhanced pharmacokinetics, inaccessible via the genetic code. Homoserine at ligation junctions (Thr37Hse, Met76Hse) acts as benign surrogates, maintaining integrity while enabling efficient amide formation. Norleucine replaces methionines to prevent oxidation. Ornithine at position 116 allows targeted modulation of immune cell responses. PEGylation at a nearby serine (S113Orn) yielded the inverse selectivity.

Citation: Ninomiya et al., 2025

Cytokines like IL-4 are powerful immunomodulators but notoriously difficult to engineer for therapeutic use. They activate multiple receptor complexes on different cell types, making selectivity a challenge. Standard protein engineering, limited to the 20 natural amino acids, cannot independently optimise selectivity, pharmacokinetics, and activation simultaneously.

Multiple ncAAs working together solved this for IL-4: homoserine at ligation junctions maintained structural integrity during chemical synthesis; norleucine replaced oxidation-prone methionines for stability; ornithine at position 116 modulated immune cell selectivity; and PEGylation via an ncAA handle at a nearby position extended half-life. Notably, PEGylation at different sites produced inverse receptor selectivity profiles (Ninomiya et al., 2025).

This multi-ncAA approach, where several non-canonical residues each address a different pharmacological parameter, exemplifies the advantage of an expanded genetic code. Rather than compromising on one property to improve another, each ncAA handles a specific engineering challenge independently.

Source publication